Posted 12/11/2023, 10:45:18 PM
Johnson & Johnson Stock Outperforms Market But Faces Headwinds in 2023
- Johnson & Johnson (JNJ) stock has outperformed the S&P 500 over the past month, gaining 4.87% vs 5.28% for the S&P
- JNJ is expected to report 0.85% higher EPS and 11.75% lower revenue in its next quarterly report
- For the full fiscal year, analysts forecast a 1.08% drop in JNJ's EPS and a 10.81% revenue decline
- JNJ currently has a Zacks Rank of #3 (Hold) and a Forward P/E ratio of 15.39, on par with industry averages
- The Large Cap Pharmaceuticals industry ranks in the top 21% of Zacks Industries, suggesting continued outperformance potential